News|Videos|November 7, 2023

Bispecific Therapies in RRMM: Teclistamab, Talquetamab, and Elranatamab Updates

Author(s)Sagar Lonial, MD, FACP, FASCO, Luciano Costa, MD, PhD, Cesar Rodriguez, MD

Insight into the latest updates on three approved bispecific therapies in the context of relapsed and refractory multiple myeloma, including teclistamab, talquetamab, and elranatamab, discussing response rates, administration, and side effects.

Episodes in this series

Experts on multiple myeloma

EP. 1 Evolving Treatment Paradigms in Relapsed/Refractory Multiple Myeloma

Experts on multiple myeloma

EP. 2 Earlier Use of Novel Therapeutics in Multiple Myeloma Treatment Pathways

Experts on MM

EP. 3 Patient Scenario: Management of Multiple Myeloma With Talquetamab Therapy

Experts on MM

EP. 4 Bispecific Therapies in RRMM: Teclistamab, Talquetamab, and Elranatamab Updates

Experts on MM

EP. 5 Bispecific Therapies in Multiple Myeloma: Impact on Real-World Practice

Experts on MM

EP. 6 Adverse Events With Bispecific Therapy: Dysgeusia, Skin, and Nail Changes

Experts on MM

EP. 7 Managing AEs in Multiple Myeloma: Dosing and Prophylactic Strategies

EP. 8 Multiple Myeloma: Optimizing ICANS and CRS Management

EP. 8 Multiple Myeloma: Optimizing ICANS and CRS Management

$A panel of experts discusses the management of adverse effects including dysgeusia and infections among patients who received bispecific therapies for relapsed/refractory multiple myeloma in the context of a clinical case.$

EP. 9 Managing Toxicity Following Bispecific Therapy in R/R Multiple Myeloma

Experts on MM

EP. 10 Patient Scenario: Navigating Sequencing in Multiple Myeloma

Experts on MM

EP. 11 CAR-T vs BCMA Bispecifics: Navigating Myeloma Treatment Decisions

Experts on MM

EP. 12 Navigating CAR-T Therapy in RRMM: Patient Counsel and Managing AEs

EP. 13 Advancements in Multiple Myeloma IO Therapy: Key Takeaways

EP. 13 Advancements in Multiple Myeloma IO Therapy: Key Takeaways

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Related to this article

Updated NCCN Guidelines for multiple myeloma add a dedicated MRD testing framework and expand recommended MRD assessment timepoints.

September 18th, 2026

NCCN Guidelines Strengthen MRD Testing Recommendations in Multiple Myeloma

Updated NCCN Guidelines for multiple myeloma add a dedicated MRD testing framework and expand recommended MRD assessment timepoints.

Treatment Strategies in Multiple Myeloma are Changing: © stock_acc - stock.adobe.com

September 12th, 2026

Debating CAR T-Cell Therapy Vs Bispecifics at First Relapse in Myeloma

Experts discussed whether CAR T cells or bispecific antibodies should be used first in relapsed/refractory multiple myeloma at the 2026 SOHO Annual Meeting.

Trending on CancerNetwork

Lutetium Lu 177 Dotatate Biosimilar Earns Final FDA Approval in GEP-NETs

Neoantigen Vaccine Shows Encouraging Activity in Head and Neck Cancer

COA Warns That Price Negotiation for Medicare Part B Drugs Threatens Community Oncology

Using Intrathecal Dendritic Cells for Leptomeningeal Disease From Breast Cancer

Real-World Tislelizumab Combo Shows Encouraging Efficacy in ES-SCLC